Australian SaaS Medtech Platform Targets User Base Growth In Asia

Innovations and inventions in burgeoning medical technology (medtech) sector aims to improve services and products in care sector.

The Australian Securities Exchange (ASX) listed MedAdvisor Limited (ASX:MDR) provides mobile application, web application and an advanced software platform (SaaS) that supports and empower individuals and carers to manage all aspects of prescription medication use. The company's objective is to deliver the world's most effective software for personal medication management, and to help people make the best possible use of medication.

On 07/May/2019 MedAdvisor announced on ASX it entered in a new joint venture (named ZP MedAdvisor Pte Ltd) with a Singapore based Zuellig Pharma Pte Ltd that would enable MedAdvisor to reach 150 million users in Asia and further commercialise their SaaS medication management platform.

Zuellig Pharma's core value is to make healthcare more accessible. Their strengths include; strong local network of healthcare facilities, advanced cold chain facilities, and adoption of innovation driven progressive solutions for evolving health care needs.

According to the ASX announcement Philippines and Malaysia will be the initial markets to test the SaaS platform. Introduction of early stage innovative technology in Asian market indicate the importance of Asian market for disruptive products and services.


  1. Very informative article on healthtech and medtech, thanks!

  2. Its going to be a very strong distribution network for AU:MDR.


Post a Comment

Popular posts from this blog

Recommendation to Youtube to allow auto publish Linkedin user videos

Content piracy challenge: perceived versus actual loss of revenue, and tackling it.